Biomarkers in Barrett’s esophagus and esophageal adenocarcinoma: Predictors of progression and prognosis
Open Access
- 1 January 2010
- journal article
- review article
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 16 (45) , 5669-5681
Abstract
Barrett's esophagus is a well-known premalignant lesion of the lower esophagus that is characterized by intestinal metaplasia of the squamous epithelium. It is clinically important due to the increased risk (0.5% per annum) of progression to esophageal adenocarcinoma (EA), which has a poor outcome unless diagnosed early. The current clinical management of Barrett's esophagus is hampered by the lack of accurate predictors of progression. In addition, when patients develop EA, the current staging modalities are limited in stratifying patients into different prognostic groups in order to guide the optimal therapy for an individual patient. Biomarkers have the potential to improve radically the clinical management of patients with Barrett's esophagus and EA but have not yet entered mainstream clinical practice. This is in contrast to other cancers like breast and prostate for which biomarkers are utilized routinely to inform clinical decisions. This review aims to highlight the most promising predictive and prognostic biomarkers in Barrett's esophagus and EA and to discuss what is required to move the field forward towards clinical application.Keywords
This publication has 100 references indexed in Scilit:
- Molecular basis of Barrett’s oesophagus and oesophageal adenocarcinomaGut, 2006
- Concordance among Gene-Expression–Based Predictors for Breast CancerNew England Journal of Medicine, 2006
- Comparative isoschizomer profiling of cytosine methylation: The HELP assayGenome Research, 2006
- TP53 and progression from Barrett’s metaplasia to oesophageal adenocarcinoma in a UK population cohortGut, 2006
- High-throughput DNA methylation profiling using universal bead arraysGenome Research, 2006
- REporting recommendations for tumour MARKer prognostic studies (REMARK)British Journal of Cancer, 2005
- Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cellsNature Genetics, 2005
- Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression riskOncogene, 2005
- Gene expression profiling predicts clinical outcome of breast cancerNature, 2002
- The Hallmarks of CancerCell, 2000